What is Recursion?
Recursion operates at the vanguard of the digital biology revolution, utilizing its proprietary Recursion Operating System to decode complex biological and chemical interactions. By integrating automation, high-throughput experimentation, and sophisticated algorithmic analysis, the company aims to bypass traditional, bias-prone drug discovery methods. Its market position is defined by the Recursion Map, a comprehensive suite of software tools that enables the firm to navigate foundational biology with unprecedented speed and precision. This technological infrastructure allows Recursion to scale its research capabilities, effectively transforming the drug development pipeline into a data-driven, iterative process that promises to accelerate the delivery of life-saving therapies to patients globally.
How much funding has Recursion raised?
Recursion has raised a total of $514.5M across 10 funding rounds:
Multiple Rounds
$4.9M
Series A
$15M
Debt
$4M
Series B
$60M
Other Financing Round
$20.5M
Series C
$121M
Series D
$239M
Other Financing Round
$50M
Debt (2015): $830K, investors not publicly disclosed
Unspecified (2015): $1.5M led by National Institutes of Health
Angel/Seed (2015): $2.6M supported by Advantage Capital Partners
Series A (2016): $15M featuring Epic Ventures, Lux Capital, Wild Basin Investments, AME Cloud Ventures, Obvious Ventures, and Data Collective
Debt (2017): $4M backed by Square 1 Bank
Series B (2017): $60M with participation from Data Collective
Other Financing Round (2018): $20.5M led by Square 1 Bank
Series C (2019): $121M supported by Mubadala Ventures, Lux Capital, Data Collective, Texas Tech University System, Menlo Ventures, Intermountain Ventures, AME Cloud Ventures, Scottish Mortgage Investment Trust PLC, Epic Ventures, CRV, Two Sigma Ventures, Felicis Ventures, and Obvious Ventures
Series D (2020): $239M featuring Samsara BioCapital, Obvious Ventures, Laurion Capital Management, Baillie Gifford International, Lux Capital, Catalio Capital Management, Mubadala, Two Sigma Ventures, Casdin Capital, DCVC, Leaps by Bayer, Intermountain Ventures, Advantage Capital, Felicis Ventures, and EPIC Ventures
Other Financing Round (2023): $50M backed by NVIDIA
Key Investors in Recursion
Data Collective
A venture capital firm focused on deep tech and data-driven companies that are solving complex, real-world problems through scientific and engineering breakthroughs.
Lux Capital
A multi-stage investment firm that backs entrepreneurs who are building the future through emerging technologies in science and engineering.
NVIDIA
A global technology leader specializing in GPU design and AI computing solutions that power high-performance research and machine learning applications.
What's next for Recursion?
With the infusion of recent capital, Recursion is poised to further expand its computational infrastructure and accelerate its clinical pipeline. The strategic focus remains on enhancing the Recursion Map to uncover novel biological insights that were previously inaccessible. As the company transitions into more advanced stages of development, the emphasis will likely shift toward scaling its industrial-grade drug discovery platform and forging deeper partnerships with global technology and pharmaceutical entities. By maintaining its commitment to unconstrained biological exploration, Recursion is well-positioned to redefine the economics of drug development and solidify its role as a critical player in the future of precision medicine.
See full Recursion company page
